Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics-Reference-Cited by-同舟云学术

Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics

Published:2021-11 Issue:11 Volume:43 Page:1812-1826.e7
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Risebrough Nancy A.,Baker Timothy M.^ORCID,Zhang Lirong,Ali Sarah N,Radin Michael,Dang-Tan Tam

Funder

Novo Nordisk

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference45 articles.

1. Pathogenesis of type 2 diabetes mellitus;DeFronzo;Med Clin North Am,2004

2. Diabetes mellitus;Triplitt,2011

3. Centers for Disease Control and Prevention, National Diabetes Statistical Report 2020: Estimates of Diabetes and its Burden in the United States. 2020.

4. Centers for Disease Control and Prevention. Type 2 Diabetes. Diabetes Basics [Internet] 2019 May 30, 2019 [cited 2021 Jun 30].

5. The impact of diabetes on employment and work productivity;Tunceli;Diabetes Care,2005

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Risk preferences over health: Empirical estimates and implications for medical decision-making;Journal of Health Economics;2024-03

3. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China;Frontiers in Pharmacology;2023-08-09

4. A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus;PharmacoEconomics;2023-07-06

5. Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial;Obesity;2023-03-06